- Home
- NEOV vs ENTX Comparison
NEOV vs ENTX Comparison
Compare NEOV & ENTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NEOV | ENTX |
|---|---|---|
| Founded | 2018 | 2010 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 127.5M | 147.4M |
| IPO Year | 2022 | 2015 |
Fundamental Metrics
Financial Performance| Metric | NEOV | ENTX |
|---|---|---|
| Price | $2.17 | $2.92 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 5 |
| Target Price | $9.75 | $9.75 |
| AVG Volume (30 Days) | ★ 1.3M | 671.8K |
| Earning Date | 11-09-2026 | 11-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ 0.22 |
| Revenue | ★ $13,332,953.00 | $42,000.00 |
| Revenue This Year | $623.96 | N/A |
| Revenue Next Year | $344.27 | N/A |
| P/E Ratio | ★ N/A | $13.68 |
| Revenue Growth | ★ 58.22 | N/A |
| 52 Week Low | $1.36 | $0.91 |
| 52 Week High | $7.13 | $4.20 |
Technical Indicators
Market Signals| Indicator | NEOV | ENTX |
|---|---|---|
| Relative Strength Index (RSI) | 38.29 | 53.62 |
| Support Level | $2.03 | $2.71 |
| Resistance Level | $3.21 | $3.08 |
| Average True Range (ATR) | 0.18 | 0.20 |
| MACD | -0.02 | 0.05 |
| Stochastic Oscillator | 12.56 | 55.76 |
Price Performance
Historical ComparisonAbout NEOV NeoVolta Inc.
NeoVolta Inc is engaged in designing, manufacturing, and selling high-end Energy Storage System which can store and use solar energy via batteries and an inverter at a residential site. Its marketplace includes the solar industry, installers, new construction homebuilders, home remodelers, and homeowners. Its ESS product portfolio includes the NV14, NV24, NVPlus, NV7600 stand-alone inverter, and the NV16 kW AC hybrid inverter with 24 kW PV input and a 250 kW / 430 kWh C&I system.
About ENTX Entera Bio Ltd.
Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to perform. Its product candidates are: EB613, which is being developed as an oral, osteoanabolic (bone-building) tablet treatment for osteoporosis; EB612, being developed as an oral PTH(1-34) tablet peptide replacement therapy for patients with hypoparathyroidism; EB618, an Oral GLP-1 being developed to tackle obesity; and Oral GLP-2, a peptide tablet alternative for patients suffering from short bowel syndrome. The company operates in Israel.